By Colin Kellaher

 

Johnson & Johnson's Janssen Pharmaceutical Cos. unit and Legend Biotech Corp. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of their cell-based therapy Carvykti for certain patients with the blood cancer multiple myeloma.

The companies said the recommendation covers Carvykti for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have shown disease progression on the last therapy.

Janssen and Legend, a Somerset, N.J.-based biotechnology company, in late 2017 struck an exclusive world-wide license and collaboration agreement to develop and commercialize Carvykti.

The U.S. Food and Drug Administration last month approved Carvykti, making it the first customized, cell-based treatment in the U.S. to be developed initially in China.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

March 25, 2022 08:34 ET (12:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Johnson and Johnson Charts.